^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ACLX-001

    i
    Other names: ACLX-001, ARC-T/sparX-BCMA, SPRX001 (bivalent BCMA-specific adapter) with universal CAR-modified T cell (ARC-T cells), ARC-T/SPRX001
    Company:
    Arcellx, Gilead
    Drug class:
    BCMA-targeted CAR-T immunotherapy
    Related drugs:
    10ms
    ARC-101: Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma (clinicaltrials.gov)
    P1, N=65, Recruiting, Arcellx, Inc. | Trial primary completion date: Aug 2022 --> Aug 2024
    Trial primary completion date
    |
    ACLX-001 • anitocabtagene autoleucel (CART-ddBCMA)